Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.




## 上 海 復 星 醫 藥( 集 團 ) 股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)


(Stock Code: 02196)




As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive directors of the Company are Dr. Zhang Weijiong, Mr. Cao Huimin, Mr. Jiang Xian and Dr. Wong Tin Yau Kelvin.

\* for identification purposes only

#### **1. IMPORTANT NOTICE**



2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP



<sup>E</sup> <sup>K</sup> ¶ <sup>K</sup> ¶ <sup>K</sup> ¶ <sup>K</sup> ¶ <sup>K</sup> ¶ <sup>K</sup> ¶		, I: <sub>I</sub>	C, ., : M
Items	Amounts during the Reporting Period (Jul – Sep 2015)	Amounts from the beginning of the year to the end of the Reporting Period (Jan – Sep 2014)	Description
and the provided of the provid	97,665,175.84	191,310,773.56	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			

. L : 10

,, h, h, ,						73,142
The	shareholding s	status of the <b>T</b>	op 10 sharehol	ders		
	Shareholding at the end of	Percentage	Number of restricted	-	Shares pledged or locked up	
Name of shareholders (full name)	the period	(%)	shares held	Status	Number	
HANGHAI F <b>Q</b> NHIGH ECHN <b>Q</b> L <b>Q</b> G (G <b>Q</b> ) C <b>Q</b> M AN LIMI ED ("F <sub>r</sub> G <sub>r</sub> ")	920,641,314	39.83	0	Ŋ.	0	D, , , , , , , , , , , , , , , , , , ,
HK CC NOMINEE LIMI ED (N 1)	402,619,300	17.42	0	v v j v	0	
CHINA EC I IE FINANCE CO A ION LIMI ED	69,112,399	2.99	0	Ŋ.	0	* * , *
NA IQNAL QCIAL EC I F ND 104 FQLIQ	37,199,998	1.61	0	Ŋ.	0	+ +, +
HONG KONG EC I IE CLEA ING COM AN LIMI ED (N 2)	33,556,005	1.45	0	Ŋ.	0	* * 2 *
CEN ALH IJIN NE MEN LD.	24,067,700	1.04	0	Ŋ.	0	
<ul> <li>✓ INH A LIFE IN ANCE CQ., L D.</li> <li>— DI IDEND — G Q DI IDEND</li> <li>→ 018L — FH001 HANGHAI*</li> </ul>	22,652,864	0.98	0	Ŋ.	0	* *, *
ING CA I AL (BEIJING) CQ., L D — ING CA I AL G Q H F ND NQ. I*	17,695,247	0.77	0	Ŋ.	0	, .
FQ IC ING ELEC ED 1*	16,764,537	0.73	0	Ŋ.	0	
ING AN CO, L D — ELI E IN E MEN • ING CA I AL	16,567,783	0.72	0	Ŋ.	0	, , , , , , ,

The shareholding status	s of the Top 10 unrestric	ted shareholders	
	Number of	Type and num	ber of shares
Name of the shareholders	unrestricted tradable shares held	Туре	Number
E, G, I,	920,641,314	MB, L h	920,641,314
HK CC NOMINEE LIMI ED (Note 1)	402,619,300		402,619,300
CHINA EC I IE FINANCE CO O A ION LIMI ED	69,112,399	MB, MB	69,112,399
NA QNAL QCIAL EC I F ND 104	37,199,998	MB, MB	37,199,998
HQNG KQNG EC I IE CLEA ING CQM AN LINII ED (Note 2)	33,556,005	MB, MB, MB, MA	33,556,005
CEN ALH IJIN NE MEN LD.	24,067,700	MB	24,067,700
<pre></pre>	22,652,864	MB , h	22,652,864
ING CA I AL (BEIJING) CQ., L D — ING CA I AL G Q H F ND NQ. I*	17,695,247	MB, the heat	17,695,247
FQ_IC JING ELEC ED 1*	16,764,537	MB L	16,764,537
ING AN CQ., L D — ELI E IN E MEN • ING CA I AL	16,567,783	MB	16,567,783
D , , , , , , , , , , , , , , , , , , ,	Ġ 💽 H F ND NQ.	BEIJING) CO., L D – I*, FO IC ING E 	LEC ED 1* ING ING CAIAL IJING) CQ., L D.
	N. ANIL	<b>₩</b> <sup>₩</sup> <sup>₩</sup> <sup>₩</sup>	

Note 1: HK CC NOMINEE LIMI ED,  $\dots$  H,  $K_{r_1}$  Y,  $C_{r_1}$  C, N L, N L,

#### 3. SIGNIFICANT EVENTS



	Balance Sheet						
Items	Closing balance as at the end of the period	Opening balance as at the beginning of the year	Ratio of change	Reasons 👞			
Qh y hwy	485,549,599.95	198,755,576.52	144.29%	Marine and the second s			
		990,340,787.62	-100.00%	(N, )			
	3,494,730.03	11,246,964.92		^N¦≩ № ` u^N), (N ` )			
	3,529,897,004.62	2,499,156,438.67	41.24%				
	167,214,321.23	89,379,481.02	87.08%	$M_{i_1} = b_{i_1} + c_{i_2} + c_{i_3} + c_{i_4} + c_{i_1} + c_{i_1} + c_{i_2} + c_{i_1} + c_{i_2} + c_{i_1} + c_{i_2} + c_{i_3} + c_{i_4} + c_{i_5} + c_{i$			
k, - r×	4,508,065,870.77	2,841,223,392.47	58.67%				
×¶ *×¶×¶!	474,418,367.92	342,926,461.15	38.34%				
	14,831,357.70	1,279,819.25	1,058.86%				
$ \begin{array}{c} {}^{\mathrm{L}} \lambda_{\mathbf{q}} \left[ \lambda_{\mathbf{q}} \right] \lambda_{\mathbf{q}} \left[ $		589,118,424.34	-100.00%	(N, )			
	2,822,255,623.13	1,109,525,523.85	154.37%	Μլս, լջին, լս, ս, ս, լսիս ՀՀԿԱ, լս,պել ջ, Կել է			
	63,116,411.43	1,070,561,681.96	-94.10%				
L-1- K	1,618,247,844.35	771,191,646.56	109.84%				
B,	1,894,480,886.28	3,085,482,735.30	-38.60%				

		Income State	ement	
	Current amount	Amount of the last period		
Items	Jan – Sep 2015	Jan – Sep 2014	Ratio of change	Reasons
Fi A	339,686,256.62	251,024,209.33	35.32%	
A tot r	33,340,027.70	11,784,007.60	182.93%	
Get a star the set	3,506,487.53	-9,516,778.44	136.85%	
Net NI NI	63,499,502.52	38,512,060.43	64.88%	
Net NI C	10,862,409.73	15,531,263.99	-30.06%	
Qhe so y he in the	-279,141,519.38	146,057,212.28	-291.12%	

Statement of Cash Flow					
	Current amount	Amount of the last period			
Items	Jan – Sep 2015	Jan – Sep 2014	Ratio of change	Reasons	
	1,161,951,526.99	843,637,595.71			
	764,402,303.12	1,793,987,740.16			

 Note:
 I 2014, C
 2014, C

 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I</t

2015, 41 ( <sub>1</sub>) <u>n</u> n' Ιé Iκ N N7 \_ 

 MB10.82
 47
 47
 4
 4
 M, b
 2015, b
 C

 C...L.\*
 A
 I
 "(b)"
 F
 (G)"
 (G)"

 於上海
 星醫藥(集團)股份有限公司股權激勵計劃意見的函》(上市部函 2015, 215號))
 215
 (《關

  $\begin{array}{c} \mathbf{L} \\ \mathbf{L} \\ \mathbf{C} \\ \mathbf{U} \\ \mathbf{U} \end{array}$ Į,, II.  $\begin{array}{c} 25 \text{ A}_{111} \\ 1 \text{ B}_{111} \\ 2015, 1 \\ 2013 \\ 1 \text{ C}_{111} \\ 2013 \\ 1 \text{ C}_{111} \\ 1 \text{ C}_{111}$ ι,  $\begin{array}{c} \mathbf{B} \\ \mathbf{C} \\ \mathbf{$ ι<sub>τ</sub> **ب**\_\_) ) ا Ç k, Α ), II 🖡 ۲° Ç IIU 2,719,000 т 🖉 · • • • • • • • 2,704,000 I, , I, I, Ç в, h . ۰<sub>1</sub>, ۲ ۹<sub>1</sub> Î Ç , A 🎚 Η L C ex (2) I 2013 

 I
 2015, C
 "N
 A,

 i
 2015, C
 "N
 A,

 i
 2015, M
 2015, M
 Signature


 i
 2015, M
 N
 A,

 i
 N
 A,
 Fig., M
 I


 i
 A,
 A,
 A,
 Fig., M
 I

 i
 A,
 A,
 A,
 A,
 Fig., M
 I

 i
 A,
 A,
 A,< Č ι,<u>⊆</u>γ Ér 🦷 **( )** Ç L N L B E 🚬 -I 🦆 ( t 



3.3		, ↓ I Ç	en in the second	•, •, •, · · · · · ·	5%, 4	
Background	Туре	Covenantors	Undertakings	Validity period	Whether duration specified	Whether timely and



Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* L 29 2015

#### **APPENDICES** 4.

#### 4.1 Financial statements

### **Consolidated balance sheet**

30 September 2015

# : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

	: <sub>LX</sub> C <sub>L</sub> , : MB	
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
	3,516,813,404.78	3,695,698,185.8
$\mathbf{L}_{\mathbf{E}}$ , $\mathbf{E}$ , $\mathbf{J}_{\mathbf{E}}$ , $\mathbf{L}_{\mathbf{E}}$ , $L$		
	38,724,495.54	33,770,584.1
	408,527,911.80	472,523,132.7
	1,789,464,377.02	1,504,149,790.7
	136,605,468.61	137,690,114.0
	677,257.70	1,023,889.4
	16,983,973.47	14,264,402.9
	485,549,599.95	198,755,576.
	1,627,321,198.79	1,604,562,390.
		990,340,787.
	3,494,730.03	11,246,964.9
	8,024,162,417.69	8,664,025,819.1
Non-current assets.		
Clever and the second		
$A_{1} \underbrace{\mathbf{u}_{1}}_{\mathbf{x}_{1}} = \underbrace{\mathbf{u}_{1}}_{\mathbf{x}_{1}} \underbrace{\mathbf{u}_{2}}_{\mathbf{x}_{1}} \underbrace{\mathbf{u}_{2}}_{\mathbf{x}_{2}} \underbrace{\mathbf{u}_{2}} \underbrace{\mathbf{u}_{2}}_{\mathbf{x}_{2}} \underbrace{\mathbf{u}_{2}} \underbrace{\mathbf{u}_{2}$	3,529,897,004.62	2,499,156,438.0
$L_{r_1}^{k} = \mathbf{V}, \ \mathbf{u}_{\mathbf{k}-\mathbf{r}}$		
	13,489,435,775.47	11,905,750,117.
Fu <sup>°</sup>	4,720,292,409.25	4,623,958,317.0
	964,172,888.14	1,051,988,109.
	3,233,982.94	5,450,698.
	2,857,317,020.41	2,822,483,093.
	167,214,321.23	89,379,481.
G, i,	3,292,538,591.11	3,255,041,739.
	11,804,369.09	13,583,440.
D	92,366,614.48	101,221,671.
	262,125,551.28	304,238,328.4
	29,390,398,528.02	26,672,251,436.
	37,414,560,945.71	35,336,277,255.

#### **Consolidated balance sheet** (*Continued*)

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:	of the renou	of the rear
	4,508,065,870.77	2,841,223,392.47
B. t. K. M. S. F. S. F.	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	_,,,.,
É, N. J. M. M. J. N.		
B	67,928,606.53	70,987,451.05
	874,465,599.33	833,974,948.21
	226,002,022.22	266,518,255.34
$\underline{G}_{\mathbf{L}} = (\mathbf{J}_{\mathbf{L}}, \mathbf{J}_{\mathbf{L}}, \mathbf{J}_{\mathbf{L}}$		
FI CONCERNING OF A CONCERNINTE OF A CONCERNINTE A CONCERNINTE A CONCERNINTE A CONCERNINTE A CO		
	296,895,628.48	298,472,746.11
	474,418,367.92	342,926,461.15
	166,803,873.32	177,075,081.31
	14,831,357.70	1,279,819.25
	1,379,103,280.44	1,935,656,885.83
		589,118,424.34
$\frac{1}{ \mathbf{N}_{i} _{i}} = \frac{1}{ \mathbf{n}_{i} _{i}} + \frac{1}{ \mathbf{n}_{i} _{i}}$	2,822,255,623.13	1,109,525,523.85
	63,116,411.43	1,070,561,681.96
	10,893,886,641.27	9,537,320,670.87
Non-current liabilities:	10,000,000,000,000,000	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
L	1,618,247,844.35	771,191,646.56
B, the	1,894,480,886.28	3,085,482,735.30
	890,883,419.71	710,056,624.65
	178,123,561.73	139,593,190.51
	1,934,427,964.42	1,929,331,107.42
	73,391,869.13	60,299,392.99
	6,589,555,545.62	6,695,954,697.43
Fanity: N	17,483,442,186.89	16,233,275,368.30
Equity.		0.011.011.001.00
	2,311,380,364.00	2,311,611,364.00
	6,049,708,237.59	6,123,454,191.14
The second secon	838,468,407.81	1,120,365,125.73
	1,662,373,054.64	1,662,373,054.64
	1,002,575,054.04	1,002,373,034.04
	6,700,890,376.05	5,457,045,050.64
E to set to a set to	0,700,070,070	2, 127, 010, 000, 01
	17,562,820,440.09	16,674,848,786.15
N. 3. July 1 M.	2,368,298,318.73	2,428,153,101.51
	19,931,118,758.82	19,103,001,887.66
	37,414,560,945.71	35,336,277,255.96

Legal Representative: Chen Qiyu

Chief Financial Officer: Guan Xiaohui Director of the Accounting Department: Yan Jia

### **Balance Sheet of the Parent Company (***Continued***)**

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
k,	1,834,226,000.00	
Figure 1 and 1 and 1		
Bu		
	78,632,661.11	72,568,579.44
	23,932,653.33	21,842,286.49
	147,159,729.00	160,716,398.26
Dut	1,364,923.50	1,062,450.00
Qa VV	453,068,674.16	587,606,051.26
	2,641,935,028.99	1,037,216,423.85
		998,894,520.55
	5,180,319,670.09	2,879,906,709.85
Non-current liabilities:		
L <sub>r</sub> , -	186,740,000.00	85,000,000.00
B	1,894,480,886.28	3,085,482,735.30
D	1,525,000.00	1,750,000.00
	1,209,260,573.79	1,192,857,263.79
	3,292,006,460.07	4,365,089,999.09
	8,472,326,130.16	7,244,996,708.94
Equity:		
	2,311,380,364.00	2,311,611,364.00
	8,227,835,906.44	8,270,816,715.22
<u>, , , , , , , , , , , , , , , , , , , </u>		
	55,747,958.04	224,689,817.57
	949,985,460.52	949,985,460.52
	4,193,926,575.18	2,839,595,396.66
	15,738,876,264.18	14,596,698,753.97
	24,211,202,394.34	21,841,695,462.91

Legal Representative: Chen Qiyu

Guan Xiaohui

Chief Financial Officer: Director of the Accounting Department: Yan Jia

### **Consolidated Income Statement**

January – September 2015



# : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

		ì		
	., L∶	ις C <sub>L</sub> , :	MB • · · ·	. с.: " <sub>А.</sub> с. –
Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
I. J. L.	3,152,113,519.72	3,122,905,282.64	9,073,497,568.10	8,661,444,631.29
	3,152,113,519.72	3,122,905,282.64	9,073,497,568.10	8,661,444,631.29
	, , ,		, , ,	, , ,
E I.				
F				
II. Just have	2,895,782,154.22	2,841,148,358.80	8,300,064,068.03	8,033,810,333.58
	1,549,543,653.59	1,718,871,717.37	4,479,008,803.33	4,905,488,021.73
	-,,	-,,,,,,	.,,	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F yr yr Ulyr yr				
C				
A t t t				
B <sub>1</sub> t yr yw yw	24,497,548.36	23,567,831.20	74,510,036.45	59,883,149.42
	752,785,285.93	589,494,712.71	2,033,469,048.98	1,606,792,320.56
A	439,321,906.97	417,425,034.77	1,340,049,894.95	1,198,838,624.94
FL	118,030,107.88	91,347,934.22	339,686,256.62	251,024,209.33
A	11,603,651.49	441,128.53	33,340,027.70	11,784,007.60

### **Consolidated Income Statement (***Continued***)**

January – September 2015

Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
L <b>Qh</b> sy <sub>a</sub> ha q usy	-503,674,636.21	170,383,244.67	-279,141,519.38	146,057,212.28
Qh s, h, h, ts, s, h t <sub>h</sub> t <sub>h</sub> s. h s, t <sub>h</sub> s, h s, t <sub>h</sub> s, t <sub>h</sub> s.	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
1. <b>Φ</b> <sup>1</sup> , <b>Ψ</b> <sup>1</sup> , <b>Ψ</b> <sup>1</sup> , <b>Ψ</b> <sup>1</sup> , <b>Γ</b>				
(ii) <b>Qh</b> ,, <b>b i i i i i</b>	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
ای جانب رو افران را از	732,427.55	-9,352.18	-195,739,333.69	-5,108,705.95
	-440,970,255.91	171,599,596.74	-16,216,735.14	149,088,050.35
3. Gu				
	-65,806,450.80	-1,851,673.11	-69,940,649.09	3,828,899.96
<u> </u>	2,369,642.95	644,673.22	2,755,198.54	-1,751,032.08
II. Just h. C. C. J. h. C.	157,117,103.71	812,100,177.38	1,897,755,696.77	1,940,074,283.26
	81,440,708.74	726,766,676.07	1,609,072,739.39	1,722,392,108.74
a production of the second sec	75,676,394.97	85,333,501.31	288,682,957.38	217,682,174.52
III. E. t. t. t.				
	0.25	0.24	0.82 0.82	0.69
	0.25	0.24	0.82	0.69

Legal Representative: Chen Qiyu

Guan Xiaohui

Chief Financial Officer: Director of the Accounting Department: Yan Jia

		I 🚺

### **Consolidated Statement of Cash Flow**

January – September 2015

•



### Consolidated Statement of Cash Flow (Continued)

January – September 2015

Items	Current Amount (January – September)	Amount of the Last Period (January – September)
III. Cash flow generated from financing activities:		
	87,721,195.00	1,445,949,451.00
$I_{3,1}(\mathbf{t}_1;\mathbf{s}_2,\mathbf{k}_{-3},\mathbf{t}_{-1},$	87,721,195.00	38,269,850.07
	5,110,056,682.54	3,475,109,758.30
	398,929,000.00	1,000,000,000.00
$\mathbf{Q}$ $\mathbf{V}_{1}$ $\mathbf{h}_{2}$ $\mathbf{U}_{1}$ $\mathbf{U}_{1}$ $\mathbf{U}_{1}$ $\mathbf{U}_{2}$ $\mathbf{U}_{2}$ $\mathbf{U}_{1}$ $\mathbf{U}_{1}$ $\mathbf{U}_{1}$	40,140,014.05	21,733,509.09
	5,636,846,891.59	5,942,792,718.39
	3,519,139,442.58	1,623,242,732.68
	1,114,614,719.91	1,012,768,967.52
	268,686,768.21	133,554,721.22
	238,690,425.98	1,512,793,278.03
	4,872,444,588.47	4,148,804,978.23
	764,402,303.12	1,793,987,740.16
IV. Effects of exchange rate fluctuations on cash and cash equivalents	5,949,548.99	14,780,312.38
V. Net increase of cash and cash equivalents		

#### Statement of Cash Flow of the Parent Company

January – September 2015



	, MB	
Items	Current Amount (January – September)	Amount of the Last Period (January – September)
I. Cash flow generated from operating activities:		
I. Cash flow generated from operating activities:	450,000.00	450,000.00